In this session panelists will first explore the economic and financial toll of health inequities in hindering access to affordable health care, including drugs and treatments as well as participation in clinical trials. Conversely, they will review measures that policymakers and industry—particularly within the C-suite—can take to effect meaningful change in making the health-care and research ecosystem more equitable and affordable. Participants will be encouraged to learn the role new investments can assume in driving meaningful change from the top decision makers.